The 6 Dimensions Capital-backed cancer immunotherapy developer has raised more than $200m in funding and has filed to raise up to $100m.
6 Dimensions Capital, the investment firm co-founded by pharmaceutical company WuXi AppTec, will have a chance to exit US-based immuno-oncology drug developer iTeos Therapeutics, which filed for a $100m initial public offering on Wednesday.
Founded in 2011, iTeos is working on cancer immunotherapies and plans to channel the IPO proceeds into the clinical development of a small molecule drug candidate called EOS-850 and an antibody-based candidate dubbed EOS-448.
Université catholique de Louvain’s Vives Louvain Technology Fund joined Ludwig Institute…
